Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia

Clinical Infectious Diseases

Volumn 58, Issue 10, 2014, Pages 1473-1480

  Mulenga, Lloyd ^a,b,c   Musonda, Patrick ^a,e   Mwango, Albert ^d   Vinikoor, Michael J ^a,f   Davies, Mary Ann ^g   Mweemba, Aggrey ^b   Calmy, Alexandra ^h   Stringer, Jeffrey S ^a,f   Keiser, Olivia ^b   Chi, Benjamin H ^a,f   Wandeler, Gilles ^b,i,j  

^a Centre for Infectious Disease Research   (Zambia)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ZAMBIA   (Zambia)

^d MINISTRY OF HEALTH   (Zambia)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

more..

Author keywords

Renal function; Tenofovir; Zambia

Indexed keywords

CREATININE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SEVERE RENAL IMPAIRMENT; TREATMENT OUTCOME; ZAMBIA; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; KIDNEY; KIDNEY FAILURE; PATHOPHYSIOLOGY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY; MALE; ORGANOPHOSPHONATES; RENAL INSUFFICIENCY; TENOFOVIR; ZAMBIA;

EID: 84899786511     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu117     Document Type: Article

References (29)

1. Ministry of Health, Zambia. 2007 Antiretroviral therapy protocols.Outprint Press, Lusaka, 2007.
2. Kilani B, Ammari L, Marrakchi C, et al. Seroepidemiology of HCV-HIVcoinfection in Tunisia. Tunis Med 2007; 85:121-3.
3. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine,and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.N Engl J Med 2006; 354:251-60.
4. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virusdynamics in HIV-hepatitis B virus-co-infected patients treated withtenofovir disoproxil fumarate. AIDS 2005; 19:907-15.
5. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovirdisoproxil fumarate for the treatment of HIV infection in adults: thefirst 4 years. AIDS 2007; 21:1273-81.
6. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M.Systematic review and meta-analysis: renal safety of tenofovir disoproxilfumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
7. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal functionassociated with tenofovir disoproxil fumarate treatment, compared withnucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis2005; 40:1194-8.
8. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate,chronic kidney disease and antiretroviral drug use in HIV-positivepatients. AIDS 2010; 24:1667-78.
9. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure withkidney disease risk in HIV infection. AIDS 2012; 26:867-75.
10. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovirexposure and reduced kidney function in a cohort of HIV-positivepatients: results from 10 years of follow-up. Clin Infect Dis 2013;56:567-75.
11. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated witha reduction in calculated glomerular filtration rates in the Swiss HIVCohort Study. Antivir Ther 2007; 12:1165-73.
12. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and riskfactors associated with renal impairment in HIV-infected adults in Africainitiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271-81.
13. Mulenga LB, Kruse G, Lakhi S, et al. Baseline renal insufficiency andrisk of death among HIV-infected adults on antiretroviral therapy inLusaka, Zambia. AIDS 2008; 22:1821-7.
14. Stohr W, Reid A, Walker AS, et al. Glomerular dysfunction and associatedrisk factors over 4-5 years following antiretroviral therapy initiationin Africa. Antivir Ther 2011; 16:1011-20.
15. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapyat primary care sites in Zambia: feasibility and early outcomes. JAMA2006; 296:782-93.
16. Fusco H, Hubschman T, Mweeta V, Chi B, Levy J, Sinkala M, Stringer J.Electronic patient tracking supports rapid expansion of HIV care andtreatment in resource-constrained settings. In: Third IAS Conferenceon HIV Pathogenesis and Treatment Rio de Janeiro. Brazil, 24-27July 2005; Abstract MoPe112C37.
17. Egger M, Ekouevi DK,Williams C, et al. Cohort Profile: the internationalepidemiological databases to evaluate AIDS (IeDEA) in sub-SaharanAfrica. Int J Epidemiol 2012; 41:1256-64.
18. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIVstarting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.AIDS 2012; 26:567-75.
19. Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviralexposure and renal impairment among HIV-positive persons with normalbaseline renal function: the D:A:D study. J Infect Dis 2013;207:1359-69.
20. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK.Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministrationwith lopinavir/ritonavir. J Acquir Immune Defic Syndr2006; 43:278-83.
21. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimateglomerular filtration rate. Ann Intern Med 2009; 150:604-12.
22. Inker LA, Wyatt C, Creamer R, et al. Performance of creatinineand cystatin C GFR estimating equations in an HIV-positivepopulation on antiretrovirals. J Acquir Immune Defic Syndr 2012;61:302-9.
23. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practiceguidelines for chronic kidney disease: evaluation, classification, andstratification. Ann Intern Med 2003; 139:137-47.
24. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, andprognosis of chronic kidney disease: a KDIGO Controversies Conferencereport. Kidney Int 2011; 80:17-28.
25. Fine JP, Gray R. A proportional hazards model for the subdistributionof a competing risk. J Am Stat Assoc 1999; 94:496-509.
26. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a SouthAfrican perspective. Kidney Int 2006; 69:1885-91.
27. Leport C, Bouteloup V, Rossert J, et al. Long-term evolution and determinantsof renal function in HIV-infected patients who began receivingcombination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. Clin Infect Dis 2009; 49:1950-4.
28. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovirdisoproxil fumarate-containing highly active antiretroviral therapy regimensis not observed more frequently: a cohort and case-control study.J Acquir Immune Defic Syndr 2004; 37:1489-95.
29. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R,Braden G. Tenofovir-associated acute and chronic kidney disease:a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-90.